Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects

Neurology

Volumn 63, Issue 5, 2004, Pages 865-873

  Raskin, Philip ^a   Donofrio, P D ^b   Rosenthal, N R ^c   Hewitt, D J ^c   Jordan, D M ^c   Xiang, J ^c   Vinik, A I ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; TOPIRAMATE;

ADULT; AGED; ANALGESIA; ANOREXIA; ARTHRALGIA; ARTICLE; ATTENTION; BLOOD GLUCOSE MONITORING; BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE METABOLISM; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; METHODOLOGY; MULTICENTER STUDY; NAUSEA; PAIN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SYNCOPE; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

EID: 4644369311     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000137341.89781.14     Document Type: Article

References (46)

1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
2. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol 2002;52:786-792.
3. Okuse K, Chaplan SR, McMahon SB, et al. Regulation of expression of the sensory neuron-specific sodium channel SNS in inflammatory and neuropathic pain. Mol Cell Neurosci 1997;10:196-207.
4. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998;76:151-157.
5. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 1999;96:7731-7736.
6. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-1964.
7. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311: 1047-1052.
8. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-1836.
9. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-509.
10. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 2003;19:59-68.
11. Shadiack AM, Molino LJ, Yagel SK, et al. The novel anticonvulsant topiramate is antiallodynic in a rat model of neuropathic pain. Analgesia 1999;4:173-179.
12. Potter D, Edwards KR. Potential role of topiramate in relief of neuropathic pain. Neurology 1998;50(suppl 4):A255. Abstract.
13. Bajwa ZH, Sami N, Warfield CA, Wootton J. Topiramate relieves refractory intercostal neuralgia. Neurology 1999;52:1917. Letter.
14. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000;55:1587-1588.
15. Solaro C, Uccelli MM, Brichetto G, Gaspperini C, Mancardi G. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage 2001;21:367-368.
16. Gilron I, Booher SL, Rowan JS, Max MB. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001;24:109-112.
17. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11:556-562.
18. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002;59:132-134.
19. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002;24:1576-1584.
20. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:255-261.
21. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-733.
22. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41: 968-975.
23. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76-79.
24. Jenson MG, Royal MA, Ward S, Movva V, Bhakta B, Gunyea I. Topiramate for the treatment of neuropathic and chronic pain syndromes: an open label trial. Am J Pain Med 2002;12:16-23.
25. Edwards KR, Glantz MJ, Button J. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Neurology 2000;54(suppl 3):A81. Abstract.
26. Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind, placebo-controlled trials. Acta Neurol Scand 2004;109: in press.
27. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-1178.
28. Dodson WE, Kamin M, Kraut L, Olson WH, Wu SC. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother 2003;37:615-620.
29. Rotnitzky A, Scharfstein D, Su TL, Robins J. Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring. Biometrics 2001;57:103-113.
30. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
31. Averbuch M, Katzper M. Baseline pain and response to analgesic medications in the postsurgery dental pain model. J Clin Pharmacol 2000; 40:133-137.
32. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000;49:574-579.
33. Margolis K. Gabapentin for painful diabetic neuropathy. JAMA 1999; 282:133. Letter.
34. Collins SL, Moore RA, McQuay H, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review, J Pain Symptom Manage 2000;20: 449-458.
35. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104.
36. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-128.
37. Vinik EJ, Stansberry KB, Vinik AI. Neuropathy quality of life tool (Norfolk QOL-DN) in a large clinical trial: comparison with symptom scores (NSS), nerve impairment (NISS), quantitative sensory (QST), autonomic (QAFT) tests and electrophysiology [abstract 31-LB]. In: American Diabetes Association 63rd Scientific Sessions; June 13-17, 2003; New Orleans, LA.
38. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107:165-175.
39. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978.
40. Carter BL, Small RE, Mandel MD, Starkman MT. Phenytoin-induced hyperglycemia. Am J Hosp Pharm 1981;38:1508-1512.
41. Seymour JF. Carbamazepine overdose. Features of 33 cases. Drug Saf 1993;8:81-88.
42. Penumalee S, Kissner PZ, Migdal SD. Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. Am J Kidney Dis 2003; 42:E3-5.
43. LAMICTAL® (lamotrigine) prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2003.
44. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
45. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
46. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19:870-873.